Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STG320 300 IR for house dust mite-associated allergic rhinitis
2014-004223-46Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Jul 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in house dust mite allergic rhinitis comparing STG320 300 IR with Placebo (2 arms). Primary endpoint: Total Combined Score. Started Jul 2015; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
house dust mite allergic rhinitis
Beyond the preview
Go deeper on 2014-004223-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004223-46.